CTLA4 and digestive system neoplasm: Finally, the greatest risk of grade 3–4 PAEs in patients with digestive system tumors was associated with anti-PD1 plus anti-CTLA4, which differed significantly from the other interventions except for anti-PDL1 plus anti-CTLA4, and anti-PD1 plus targeted therapy drug.